Detrimental effects of fluvastatin on plasma lipid metabolism in rat breast carcinoma model | Zendy

Andrea Kapinová | Zendy; Peter Kubatka | Zendy; Katarína Žihlavniková | Zendy; Nadežda Stollárová | Zendy; Martin Péč | Zendy; Dušan Dobrota | Zendy; Bianka Bojková | Zendy; Monika Kassayová | Zendy; Peter Orendáš | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Detrimental effects of fluvastatin on plasma lipid metabolism in rat breast carcinoma model

Author(s) -

Andrea Kapinová,

Peter Kubatka,

Katarína Žihlavniková,

Nadežda Stollárová,

Martin Péč,

Dušan Dobrota,

Bianka Bojková,

Monika Kassayová,

Peter Orendáš

Publication year - 2013

Publication title -

acta veterinaria

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.308

H-Index - 17

eISSN - 1820-7448

pISSN - 0567-8315

DOI - 10.2298/avb1303137k

Subject(s) - fluvastatin , lipid metabolism , endocrinology , medicine , cholesterol , blood lipids , breast cancer , chemistry , metabolism , animal model , pharmacology , cancer , simvastatin

From clinical practice, obvious positive effects of statins on plasma lipid metabolism are well known. On the other hand, there are several experimental rodent studies, where these beneficial effects were not confirmed. The effects of fluvastatin on selected serum lipid parameters in a rat model of experimental breast cancer were determined. The drug was dietary administered at two concentrations of 20 and 200 mg/kg. At the end of the study (experiment duration - 18 weeks) the blood from each animal was collected and serum lipid parameters were evaluated. Fluvastatin in both treated groups significantly increased parameters of serum lipids (mostly in a dose dependent manner). Fluvastatin in both treated groups of animals significantly increased serum levels of triacylglycerols, total cholesterol, and LDL-, HDL-, VLDL-cholesterol when compared to the control group. Our results pointed out to the apparent harmful effects of fluvastatin on plasma lipid metabolism in rat mammary carcinogenesis. Based on our previous results, it seems that rats commonly used in cancer model studies are generally unresponsive to the hypocholesterolemic effects of statins

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research